Literature DB >> 32641415

Plasma Gelsolin Inhibits CD8+ T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in Ovarian Cancer.

Meshach Asare-Werehene1,2, Laudine Communal3, Euridice Carmona3, Youngjin Han4,5, Yong Sang Song4,5, Dylan Burger2,3, Anne-Marie Mes-Masson3, Benjamin K Tsang6,2,7,8.   

Abstract

Although initial treatment of ovarian cancer is successful, tumors typically relapse and become resistant to treatment. Because of poor infiltration of effector T cells, patients are mostly unresponsive to immunotherapy. Plasma gelsolin (pGSN) is transported by exosomes (small extracellular vesicle, sEV) and plays a key role in ovarian cancer chemoresistance, yet little is known about its role in immunosurveillance. Here, we report the immunomodulatory roles of sEV-pGSN in ovarian cancer chemoresistance. In chemosensitive conditions, secretion of sEV-pGSN was low, allowing for optimal CD8+ T-cell function. This resulted in increased T-cell secretion of IFNγ, which reduced intracellular glutathione (GSH) production and sensitized chemosensitive cells to cis-diaminedichloroplatinum (CDDP)-induced apoptosis. In chemoresistant conditions, increased secretion of sEV-pGSN by ovarian cancer cells induced apoptosis in CD8+ T cells. IFNγ secretion was therefore reduced, resulting in high GSH production and resistance to CDDP-induced death in ovarian cancer cells. These findings support our hypothesis that sEV-pGSN attenuates immunosurveillance and regulates GSH biosynthesis, a phenomenon that contributes to chemoresistance in ovarian cancer. SIGNIFICANCE: These findings provide new insight into pGSN-mediated immune cell dysfunction in ovarian cancer chemoresistance and demonstrate how this dysfunction can be exploited to enhance immunotherapy. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32641415     DOI: 10.1158/0008-5472.CAN-20-0788

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Immunosuppressive Extracellular Vesicles as a Linking Factor in the Development of Tumor and Endometriotic Lesions in the Gynecologic Tract.

Authors:  Karolina Soroczynska; Lukasz Zareba; Magdalena Dlugolecka; Malgorzata Czystowska-Kuzmicz
Journal:  Cells       Date:  2022-04-28       Impact factor: 7.666

Review 2.  Nucleic acids and proteins carried by exosomes of different origins as potential biomarkers for gynecologic cancers.

Authors:  Miaomiao Ye; Jing Wang; Shuya Pan; Lihong Zheng; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Ther Oncolytics       Date:  2021-12-09       Impact factor: 7.200

3.  Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes.

Authors:  Meshach Asare-Werehene; Hideaki Tsuyoshi; Huilin Zhang; Reza Salehi; Chia-Yu Chang; Euridice Carmona; Clifford L Librach; Anne-Marie Mes-Masson; Chia-Ching Chang; Dylan Burger; Yoshio Yoshida; Benjamin K Tsang
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

Review 4.  Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code.

Authors:  Giuseppe Cammarata; Nadia Barraco; Ilaria Giusti; Valerio Gristina; Vincenza Dolo; Simona Taverna
Journal:  Cancers (Basel)       Date:  2022-07-13       Impact factor: 6.575

Review 5.  Crosstalk between Oxidative Stress and Exosomes.

Authors:  Wenjun Zhang; Rong Liu; Yuhua Chen; Minghua Wang; Juan Du
Journal:  Oxid Med Cell Longev       Date:  2022-08-30       Impact factor: 7.310

6.  Longitudinal profiles of plasma gelsolin, cytokines and antibody expression predict COVID-19 severity and hospitalization outcomes.

Authors:  Meshach Asare-Werehene; Michaeline McGuinty; Agatha Vranjkovic; Yannick Galipeau; Juthaporn Cowan; Bill Cameron; Curtis L Cooper; Marc-André Langlois; Angela M Crawley; Benjamin K Tsang
Journal:  Front Immunol       Date:  2022-09-06       Impact factor: 8.786

Review 7.  Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion.

Authors:  Wanjia Tian; Ningjing Lei; Junying Zhou; Mengyu Chen; Ruixia Guo; Bo Qin; Yong Li; Lei Chang
Journal:  Cell Death Dis       Date:  2022-01-18       Impact factor: 8.469

Review 8.  Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma.

Authors:  Robert Cornelison; Laine Marrah; Drew Horter; Sarah Lynch; Hui Li
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 6.208

9.  CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.

Authors:  Han Li; Fan Luo; Xingyu Jiang; Weijing Zhang; Tong Xiang; Qiuzhong Pan; Liming Cai; Jingjing Zhao; Desheng Weng; Yue Li; Yuhu Dai; Fengze Sun; Chaopin Yang; Yue Huang; Jieying Yang; Yan Tang; Yulong Han; Mian He; Yanna Zhang; Libing Song; Jian-Chuan Xia
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.